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In recent years, researchers have shown that a
large and continuously growing number of
man-made chemicals and naturally occurring
compounds can mimic endogenous estrogens
of vertebrates including humans (Colborn et al.
1993; Schlumpf et al. 2001; Soto et al. 1995).
In addition to compounds naturally occurring
in plants and some mycotoxins (Breithofer
et al. 1998; Miksicek 1994), various pesticides
and industrial chemicals have shown estrogenic
effects in vitro (Jobling et al. 1995; Klotz et al.
1996; Körner et al. 1998; Miller et al. 2001;
Soto et al. 1991; Soto et al. 1995) and in vivo
in mammals (Dodds and Lawson 1936;
Milligan et al. 1998; Nagel et al. 1997; Soto
et al. 1991) as well as ﬁsh (Christiansen et al.
2000; Donohoe and Curtis 1996; Gimeno
et al. 1996; Jobling et al. 1996). However, we
have not identiﬁed a common chemical sub-
structure responsible for the estrogenic activity
of the so-called xenoestrogens and phyto-
estrogens. The elucidation of the crystal struc-
ture of the ligand-binding domain of the
human estrogen receptor (ER)-α (Brzozowski
et al. 1997) explained, in part, this surprising
structural diversity. It revealed a ligand-binding
domain gap almost twice as large as that
required by 17β-estradiol (E2), allowing space
for a variety of other molecules to interact with
the ER. Therefore, we must assume that more
xenobiotics with unknown estrogenic activity
exist, requiring speciﬁc, sensitive, and practical
experimental screening systems for detection.
In contrast, we know comparatively little
about the interference of chemicals with the
human androgen receptor (hAR). A few deriv-
atives of the known nonsteroidal antiandrogen
bicalutamide (ICI 176,334) have shown
androgenic effects in vitro (Dalton et al. 1998),
and the bioaccumulating DDT metabolite
p,p´-DDE (dichlorodiphenyldichloroethylene),
the fungicides vinclozolin, procymidone, and
prochloraz, and the herbicide linuron (Cook
et al. 1993; Fail et al. 1995; Gray et al. 1994;
Kelce et al. 1995; Vinggaard et al. 2002)
have demonstrated androgen receptor (AR)-
mediated antiandrogenic activities in vitro
and in vivo. The two vinclozolin metabo-
lites, M1 and M2, cause antiandrogenic
effects in male rats (Kelce et al. 1994). These
metabolites (Figure 1) and linuron, but not
p,p´-DDE, relate structurally to the therapeutic 
antiandrogen ﬂutamide. The natural insecti-
cide pyrethrin and some synthetic pyrethroids
act as competitive AR antagonists in human
ﬁbroblasts (Eil and Nisula 1990). Tyler et al.
identiﬁed 3-phenoxybenzylalcohol, a metabo-
lite of the pyrethroid permethrin, as an anti-
androgen in genetically modified yeast cells
(Tyler et al. 2000). In addition, polycyclic aro-
matic hydrocarbons block AR activation
in vitro (Vinggaard et al. 2000) and suppress
androgen-dependent growth of accessory sex
organs in juvenile male rats (Chang and Liao
1987). Recently, several phenolic chemicals
demonstrated antiandrogenic activity in a
reporter cell line (Paris et al. 2002).
These examples indicate that, analogous to
xenoestrogens and phytoestrogens, a common
chemical substructure may not exist for AR-
mediated antiandrogenic activity. This stresses
the need for adequate screening systems.
Although many in vitro and in vivo bioassays
can detect ER-mediated activity, relatively few
test systems measure androgen agonist and
antagonist effects in vitro. To devise strategies
for screening new and existing chemicals, we
must test the accuracy and comparability of
existing assays. While recent comparison stud-
ies of bioassays for detection of estrogenic
activity of pure substances have revealed com-
parable results in most cases (Andersen et al.
1999; Fang et al. 2000), this work presents, for
the ﬁrst time, an interlaboratory comparison of
in vitro assays for measuring AR-mediated
androgenic and antiandrogenic activity.
Materials and Methods
Participants and test systems. All four laborato-
ries participating in this study applied cellular
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We evaluated and compared four in vitro assays to detect androgen agonists and antagonists in an
international interlaboratory study. Laboratory 1 used a cell proliferation assay (assay 1) with
human mammary carcinoma cells stably transfected with human androgen receptor. The other
laboratories used reporter gene assays, two based on stably transfected human prostate carcinoma
cells (assay 2) or human mammary carcinoma cells (assay 4), and the third based on transient
transfection of Chinese hamster ovary cells (assay 3). Four laboratories received four coded com-
pounds and two controls: two steroidal androgens, two antiandrogens, an androgenic control,
5α-dihydrotestosterone (DHT), and an antiandrogenic control, bicalutamide (ICI 176,334). All
laboratories correctly detected the androgenic activity of 4-androsten-3,17-dione and 17α-methyl-
testosterone. For both compounds, the calculated androgenic potencies relative to the positive
control (RAPs) remained within one order of magnitude. However, laboratory 3 calculated a
50-fold higher RAP for 4-androsten-3,17-dione. All assays detected and quantified the anti-
androgenic effect of vinclozolin [median inhibitory concentration (IC50) values ranging from
1.1 × 10–7 M to 4.7 × 10–7 M]. In assays 2 and 3, vinclozolin showed partial androgenic activity at
the highest concentrations tested. For vinclozolin, calculated antiandrogenic potencies relative to
bicalutamide (RAAPs) differed no more than a factor of 10, and IC50 values matched those of bicalu-
tamide. Similarly, we found antiandrogenic activity for tris-(4-chlorophenyl)methanol. RAAP values
were between 0.086 and 0.37. Three assays showed cytotoxicity for this compound at or above
1 × 10–5 M. In summary, all assays proved sensitive screening tools to detect and quantify androgen
receptor–mediated androgenic and antiandrogenic effects of these chemicals accurately, with coefﬁ-
cients of variation between 8 and 90%. Key words: androgenicity, 4-androsten-3,17-dione, anti-
androgenicity, A-SCREEN, bicalutamide, tris-(4-chlorophenyl)methanol (TCPM), vinclozolin.
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[Online 22 January 2004]test systems. Three of the four laboratories
worked with reporter gene assays with different
human and mammalian cell lines. These assays
rely on the expression of the ﬁreﬂy luciferase
gene under control of the hAR. Laboratory 1
used the A-SCREEN assay, which measures
androgen-dependent inhibition of proliferation
of an AR-positive human mammary carcinoma
cell line (Szelei et al. 1997). Table 1 lists an
overview of the four participating laboratories
and their respective test systems. All partici-
pants have previously described their assays in
the literature (Szelei et al. 1997; Térouanne
et al. 2000; Vinggaard et al. 1999; Wilson
et al. 2002) and performed them in this study
with the following modiﬁcations:
Laboratory 1 used the A-SCREEN assay.
This assay can be run in serumless or serum-
supplemented medium. The serum-free
medium does not require E2 to achieve maxi-
mal cell yield, and the serum-supplemented
medium does. Both methods give comparable
results (Szelei et al. 1997), so in conjunction
with the other assays, laboratory 1 used
serum-supplemented medium. They seeded
25,000–35,000 AR-positive MCF-7-AR1
cells in Dulbecco’s modification of Eagle’s
medium (DMEM) with phenol red and 5%
fetal calf serum (FCS) into each well of 24-well
plates. Twenty-four hours later, they changed
the medium to phenol red–free DMEM sup-
plemented with 5% charcoal–dextran-treated
FCS (CDFCS). Because these cells express ER
as original MCF-7 cells do, E2 was added to
each well, except for a control row of four wells,
to yield a ﬁnal concentration of 0.1 nM, allow-
ing maximal proliferation of MCF-7-AR1 cells.
Androgens inhibit proliferation in a concentra-
tion-dependent manner to about 30% of the
maximal cell count (Figure 2A). Under the con-
ditions of the A-SCREEN assay, the cells arrest
in G0/G1 phase (Soto et al. 1999; Szelei et al.
1997). Coincubation with an antiandrogen
blocks that inhibition of cell proliferation.
Laboratory 1 ran an extended dose–response
curve to 5α-dihydrotestosterone (DHT) with
each experiment and added DHT (to yield a
concentration of 0.1 nM) to the bottom two
rows of each plate with test compounds and
solvent controls to test for antiandrogenicity.
They left the second column in each plate as an
androgenless control. After 5 days of incuba-
tion, they ﬁxed the cells and stained them with
sulforhodamine B (SRB). They resuspended
the dye in 10 mM Tris base (pH 10.5), trans-
ferred aliquots from each well into a 96-well
plate, then calculated cell numbers from the
optical densities measured at 515 nm.
Laboratory 2 seeded stably transfected
human prostate adenocarcinoma (PC-3) cells
(PALM cells) in white opaque tissue culture
96-well plates (Becton Dickinson, Le Pont de
Claix, France). They used 20,000 cells in
150 µL HAM-F12 medium supplemented
with 3% CDFCS in each well. After an 8-hr
incubation, they added the compounds in
50 µL of the same medium without replace-
ment of the seeding medium. After 30 hr,
they removed the culture medium with the
tested compounds and replaced it with lumi-
nescent buffer (50 µL/well phenol red–free
DMEM, 3 × 10–4 M luciferin). They meas-
ured luciferase activity in intact cells with a
luminometer (Trilux Wallac; PerkinElmer,
Courtaboeuf Cedex, France). 
Laboratory 3 tested the compounds in a
reporter gene assay based on transient transfec-
tions as originally described (Vinggaard et al.
1999), but with major modifications. They
maintained Chinese hamster ovary cells
(CHO K1) in DMEM/F12 (Gibco, Paisley,
U.K.) supplemented with 100 U/mL penicillin,
100 µg/mL streptomycin, and 0.25 µg/mL
amphotericin B (Sigma-Aldrich, St. Louis,
MO, USA) and 10% FCS (BioWhitaker,
Walkersville, MD, USA). They seeded cells in
white 96-well plates (PerkinElmer Life Sciences,
Packard, Groningen, the Netherlands) at a
density of 7,000 cells/well in DMEM/F12
medium containing 10% charcoal-treated FCS
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Figure 1. Structures of the test compounds and the positive controls. Abbreviations: DHT, 5α-dihydro-
testosterone; TCPM, tris-(4-chlorophenyl)methanol.(BioWhitaker) and incubated the plates at 37°C
in a humidified atmosphere of 5% CO2/air.
After 24 hr, they transfected the cells for 5 hr
with a total of 75 ng DNA/well consisting of
the AR expression vector pSVAR0 and the
mouse mammary tumor virus-luciferase
(MMTV-LUC) reporter plasmid (both pro-
vided by A. Brinkmann, Erasmus University,
Rotterdam, the Netherlands) in a ratio of
1:100 using 0.30 µL of the transfection reagent
FuGene (Boehringer, Mannheim, Germany).
They kept the ratio of DNA (micrograms) to
FuGene (microliters) at 0.25. After removing
the transfection medium, they added the test
compounds. Laboratory 3 tested all concentra-
tions in quadruplicate. After incubation for
20 hr, they aspirated the medium and lysed the
cells by adding 20 µL/well of a lysis buffer con-
taining 25 mM trisphosphate, pH 7.8,
15% glycerol, 1% Triton X-100, 1 mM dithio-
threitol, and 8 mM MgCl2, followed by shak-
ing at room temperature for 10 min. They
measured luciferase activity directly in the cul-
ture plates using a BioOrbit Galaxy luminome-
ter (Anthos Labtec Instruments, Wals, Austria). 
Laboratory 4 carried out a test according
to the protocol previously described by
Wilson et al. (2002) with some modiﬁcations
and simplifications. They routinely main-
tained MDA-kb2 human breast carcinoma
cells in Leibowitz’s L-15 medium supple-
mented with 10% heat-inactivated (56°C,
30 min) FCS and 1% antibiotic–antimycotic
(all from Gibco) at 37°C in a humidified
incubator without CO2. They detached cells
by trypsinization and seeded them into
96-well plates at a density of about 10,000
cells/well in 100 µL medium. After cells had
attached for 24 hr, they replaced the medium
with a total of 100 µL/well of medium con-
taining various dilutions of test chemicals. In
each plate they ﬁlled four wells in one column
with medium only as the negative control,
four wells in another column with 1 × 10–10 M
DHT (final concentration) as the androgen
control, and four wells in a third column with
1 × 10–6 M bicalutamide (ﬁnal concentration)
as an antiandrogen control. They assayed each
concentration of each test compound in at least
four wells. After incubation for 24 hr, they
removed the medium and washed the cells
gently twice with phosphate-buffered saline.
To measure luciferase activity, they added
25 µL/well lysis buffer (Promega, Wallisellen,
Switzerland), transferred these into a microtiter
plate with a multichannel pipettor after
30 min, and read them on a luminometer (ML
1000; Dynex, Frankfurt/Main, Germany).
Test compounds, controls, and solvent.
Each laboratory received four commercially
available test compounds, all sent in a coded
manner, plus two control compounds. Each
laboratory used the following controls and
test compounds: androgen control, DHT
(Sigma-Aldrich, ) [laboratory 2 used methyl-
trienolone (R1881; Perkin-Elmer)]; antian-
drogen control, bicalutamide (Casodex, ICI
176,334), a gift from Zeneca Pharmaceuticals
(Macclesﬁeld, U.K.); compound 1, vinclozolin
(Dr. Ehrenstorfer, Augsburg, Germany);
compound 2, 4-androsten-3,17-dione
(Sigma-Aldrich, Taufkirchen, Germany);
compound 3, 17α-methyltestosterone (Fluka,
Taufkirchen, Germany); and compound 4,
tris-(4-chlorophenyl)methanol (TCPM)
(Lancaster, Mühlheim, Germany). 
Figure 1 illustrates the structures of the
assayed substances. Each laboratory received the
solid substances in amber glass vials with screw
caps and Teﬂon and paraﬁlm sealings. Each vial
contained the amount required to obtain 4 mL
of a 0.01 M stock solution (weighed on
microscales with an uncertainty of ± 0.05 mg).
Participants stored all substances at 4°C. The
vials of the androgen and antiandrogen controls
contained a minimum of 30 mg, which was
enough for 10 mL and 5 mL of 0.01 M stock
solution, respectively. Laboratory 2 used the
synthetic androgen R1881 instead of DHT as
an androgen control; the PALM assay has a
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Table 1. Participating laboratories and test systems.
Exposure
Laboratory Cell type End point time (hr) Statistical programa Reference
1 (Tufts University School of Medicine) MCF-7-AR1 human mammary  Cell number (determined  120 Lotus 1-2-3 (logit)  Szelei et al. 1997
adenocarcinoma cells expressing hAR with SRB assay)
2 (INSERM U 439, Pathologie  Human prostate adenocarcinoma PC-3 cells Luciferase activity 30 VBA program for  Térouanne et al. 2000
Moléculaire des Récepteurs  stably transfected with pSG5-puro-hAR EXCEL  5b (log-probit)
Nucléaires) and pMMTV-neo-Luc
3 (Danish Veterinary and Food  Chinese hamster ovary cells transiently  Luciferase activity 20 SigmaPlot [Chapman Vinggaard et al. 1999
Administration, Institute of Food  transfected with pSVAR0 expression  (three parameter);
Safety and Nutrition) vector and MMTV-LUC reporter plasmid four parameter logistic 
(for antagonists)]
4 (University of Zürich, Institute of  MDA-MB-453-KB2 human mammary carcinoma Luciferase activity 24 GraphPad Prism Wilson et al. 2002
Pharmacology and Toxicology) cells, endogenously expressing hAR and stably  (variable slope)
transfected with pMMTV-neo-Luc
aType of sigmoid regression. bProgram designed by J. Greve, Fraunhofer-Institute of Environmental Chemistry and Ecotoxicology, Schmallenberg, Germany.
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Figure 2. Concentration–response curves of androgen control, 4-androsten-3,17-dione (compound 2), and
17α-methyltestosterone (compound 3) for all four assays. (A) Assay 1. (B) Assay 2. (C) Assay 3. (D) Assay 4.
Values represent means ± SD of at least three independent experiments. lower sensitivity for DHT than for R1881
because of rapid metabolism of natural andro-
gens in PC-3 cells, as described by Térouanne
et al. (2000). These cells metabolize testos-
terone and DHT quickly, in less than 2 hr,
whereas detection of luciferase activity requires
at least 24 hr incubation with compounds.
Castagnetta et al. (1994, 1997) have reported
the ability of PC-3 cells to metabolize andro-
gens in addition to a high expression of
17β-hydroxysteroid dehydrogenase. All labora-
tories used high-purity DMSO for dissolving
test and control compounds.
All test systems showed that bicalutamide
and hydroxyﬂutamide act as potent androgen
antagonists (Ma et al. 2003; Szelei et al. 1997;
Térouanne et al. 2000; Vinggaard et al. 1999).
Although hydroxyflutamide proved more
potent than bicalutamide in assays 2 and 3
(Térouanne et al. 2000; Vinggaard et al.
1999), we selected bicalutamide as the anti-
androgen control. We used the two steroidal
androgens (compounds 2 and 3) because of
their expected different potencies. Because
Kelce et al. (1994) detected the two metabo-
lites of vinclozolin, M1 and M2, as AR
antagonists in vivo, we expected the results on
vinclozolin would provide information on the
metabolic capacities of the in vitro systems.
The persistent, bioaccumulating environmen-
tal contaminant TCPM (DeBoer 1997)
showed antiandrogenic activity in a cell prolif-
eration assay (Körner et al. 1997, 2000).
Therefore, because TCPM has high resistance
to metabolic conversion, its use offered the
opportunity to conﬁrm these results.
Performance of experiments. The laborato-
ries received instructions that each single exper-
iment must contain a)a   negative control; b)a
solvent control; c) at least ﬁve appropriate con-
centrations of the androgen control DHT that
encompass the whole range of the concentra-
tion–response curve; d) one concentration of
DHT that gives nearly maximum response
(0.1 nM) together with the following ﬁve con-
centrations of the antiandrogen control bicalu-
tamide: 0.0001, 0.001, 0.01, 0.1, and 1 µM;
e)1µM bicalutamide; f ) ﬁve (or more) con-
centrations of each test compound covering the
whole range of the concentration–response
curve (the highest concentration tested should
equal 10 µM for compounds 1, 2 and 4, and
1µ M for compound 3); and g)ﬁ ve (or more)
concentrations of each test compound together
with 0.1 nM DHT covering the whole range
of the concentration–response curve.
Each laboratory tested the compounds in
at least three independent experiments alone
and together with 0.1 nM DHT.
Quantitative evaluation. Laboratory 1
used cell number as the end point. They used
raw cell numbers for quantitative evaluation,
but for graph representation, they normalized
the experiments, set the maximum cell number
to 1, and reported ratios in relationship to this.
The three reporter gene assays (assays 2–4)
used luciferase activity relative to the hormone-
free negative control as the basic end point. For
quantitative evaluation of antiandrogenic activ-
ity, all laboratories set the luciferase activity of
the androgen control (0.1 nM DHT or R1881)
to 100%.
Each laboratory used different statistical
software (Table 1) for performance of sigmoid
regression of concentration–response curves
and calculation of median effective concentra-
tion (EC50) values for androgens and IC50
values for antiandrogens, respectively.
The androgenic potency of a test com-
pound relative to the positive control (RAP)
equals the quotient of the EC50 values of
DHT (or R1881) and the compound:
RAP = EC50 (DHT or R1881)
÷ EC50 (test compound).
The antiandrogenic potency of a test com-
pound relative to the positive control bicalu-
tamide (RAAP) equals the quotient of the IC50
values of bicalutamide and the compound. The
IC50 equals the concentration required for the
compensation of half of the androgenic effect
of 0.1 nM DHT (or R1881):
RAAP = IC50 (bicalutamide) 
÷ IC50 (test compound).
RAP and RAAP have no dimension.
Results and Discussion
Overview. The solvent control (laboratories
1–3: 0.1% DMSO; laboratory 3 also tested
0.25 and 0.5%; laboratory 4: 0.2%) showed no
signiﬁcant effect in any assay; for example, in
assay 2 the luciferase activity relative to the neg-
ative control was 0.97 ± 0.37 (n = 3). All four
laboratories correctly detected the androgenic
activity of the testosterone metabolite
4-androsten-3,17-dione and of 17α-methyl-
testosterone. All laboratories calculated similar
androgenic potencies relative to the positive
control (RAP) for both test substances and,
with the exception of 4-androsten-3,17-dione
in assay 3, fell within one order of magnitude.
Each test system detected and quantified
the antiandrogenic effect of the fungicide vin-
clozolin. Moreover, this compound showed
slight androgenic activity at the highest tested
concentrations with assays 2 and 3. Calculated
antiandrogenic potencies relative to the posi-
tive control bicalutamide (RAAP) differed less
than a factor of 10. Similarly, all assays found
antiandrogenic activity for TCPM. This chemi-
cal showed cytotoxic effects at ≥ 1 × 10–5 M in
the assays of laboratories 1, 2, and 3.
Nevertheless, all laboratories calculated RAAP
values well within one order of magnitude.
Androgens. Table 2 summarizes data on
the performance of the assays and the quantita-
tive results for the androgen control DHT (or
R1881). Assays 1 and 3 obtained EC50 values
for DHT that were 3- and 10-fold lower,
respectively, than those obtained with assay 4.
In general, assay 3 resulted in the lowest EC50
values for all three androgens tested.
One might question the comparability of
the results of assay 2 and those of the others
because of the use of two different positive
controls. However, the potency of the syn-
thetic androgen R1881 in assay 2 fell within
the range found for DHT in the other three
test systems. In all other assays, R1881 gives
comparable results, but we preferred DHT
because it is a natural androgen. 
Table 3 summarizes information on the
performance of the tests and the quantitative
results for 4-androsten-3,17-dione and
17α-methyltestosterone. Figure 2 illustrates
the concentration–response curves of both
androgens and DHT (or R1881) for all four
test systems. The coefficients of variation
(CVs) of the EC50 values of DHT (or R1881)
fell within a reasonable range (12–57%) for
all test systems (Table 2). All assays showed
acceptable repeatability for the RAP values of
the two androgenic test compounds, with
CVs between 8 and 73% (Table 3).
The cell proliferation assay showed a
3-fold dynamic range. The three reporter gene
assays revealed differences in the magnitude of
the fold induction obtained after androgen
exposure. In assays 2 and 3 the androgen con-
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Table 2. Overview of the results for the androgen control DHT.
Lowest Highest Percent induction 
No. of Replicates Concentrations concentration concentration  EC50 mean caused by 0.1 nM
Laboratory assays per assay tested (M) (M) (M) SD (M) CV (%) (mean ± SD)
15 4 1 5 1.0 × 10–12 1.0 × 10–8 7.8 × 10–11 9.3 × 10–12 12 69  ± 12
26 4 7 1.0 × 10–12 1.0 × 10–7 1.1 × 10–10a 2.3 × 10–11 22 53 ± 11
34 4 1 1 1.0 × 10–12 1.0 × 10–7 2.2 × 10–11 6.7 × 10–12 30 85 ± 11
45 4 9 1.0 × 10–12 1.0 × 10–8 2.1 × 10–10 1.2 × 10–10 57 35 ± 8
aLaboratory 2 used R1881.trol induced a luciferase activity of > 20-fold
of that of the negative control, whereas labora-
tory 4 obtained a 7-fold induction. However,
none of the parameters measured covaried
with the dynamic range.
With all assays 17α-methyltestosterone
induced about the same maximal effect as the
androgen control, thereby confirming this
compound as a full AR agonist. Assays 1–4
produced EC50 values of 4.3 × 10–10M, 7.4 ×
10–10 M, 3.3 × 10–11 M, and 5.3 × 10–10M,
respectively. 4-Androsten-3,17-dione also
induced about the same maximal effect as the
androgen control with assays 1, 2, and 3. This
compound induced only 72% of the maximal
effect of DHT with assay 4. Assays 1–4 pro-
duced EC50 values of 5.9 × 10–8M, 3.5 ×
10–8M, 2.7 × 10–10M, and 1.4 × 10–7M,
respectively. Compared with other test sys-
tems, assay 3 yielded lower EC50 values of
both compounds, as well as DHT. Because
DHT and 17α-methyltestosterone varied in
the same way, the resulting RAP value com-
pared with those of the other assays.
However, laboratory 3 found a 100-fold
lower EC50 for 4-androsten-3,17-dione than
the other groups. As this compound was rela-
tively more potent compared with DHT in
this assay, a 30- to 60-fold higher RAP than
that obtained in the other assays resulted. The
possibility that the cells used in these assays
may have different metabolic capacities may
partly explain this discrepancy. Generally,
synthetic androgens such as 17α-methyltestos-
terone resist metabolism better than natural
androgens. For example, Koh et al. (2001)
recently demonstrated that PC-3 cells rapidly
convert 4-androsten-3,17-dione predomi-
nantly to the inactive dehydroepiandrosterone
and to a lesser extent to testosterone and sub-
sequently to DHT.
Antiandrogens. Table 4 summarizes data
on the performance of the assays and the
quantitative results for the antiandrogen con-
trol bicalutamide. In all reporter gene assays,
bicalutamide showed slight but measurable
androgenic activity at the highest concentration
of 1 × 10–6 M. However, compared with the
activity induced by 0.1 nM DHT (or R1881),
we found the androgenic effect of bicalutamide
negligible (Figure 3). Laboratory 2 tested 
bicalutamide concentrations up to 1 × 10–5 M.
They found the androgenic effect low 
compared with 0.1 nM R1881 but higher than
that of 1 × 10–6M. Laboratory 1 did not detect
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Table 3. Overview of the results for the androgenic compounds 4-androsten-3,17-dione (compound 2) and 17α-methyltestosterone (compound 3).
No. of Concentrations Lowest Highest EC50 mean
Compound, laboratory assays tested concentration (M) concentration (M) (M) SD (M) RAP mean SD CV (%)
4-Androsten-3,17-dione
14 5 1.0 × 10–9 1.0 × 10–5 5.9 × 10–8 2.1 × 10–8 1.4 × 10–3 5.4 × 10–4 38
23 6 1.0 × 10–10 1.0 × 10–5 3.5 × 10–8 7.9 × 10–9 3.1 × 10–3 2.5 × 10–4 8
34 1 2 3.0 × 10–11 6.0 × 10–8 2.7 × 10–10 6.4 × 10–11 8.7 × 10–2 2.1 × 10–2 24
45 8 1.0 × 10–9 1.0 × 10–5 1.4 × 10–7 4.0 × 10–8 1.5 × 10–3 7.7 × 10–4 50
17α-Methyltestosterone
14 5 1.0 × 10–10 1.0 × 10–6 4.3 × 10–10 1.8 × 10–10 0.23 0.16 70
23 6 1.0 × 10–11 1.0 × 10–6 7.4 × 10–10 1.3 × 10–10 0.15 0.04 27
34 1 2 5.0 × 10–13 9.4 × 10–10 3.3 × 10–11 2.2 × 10–11 1.03 0.75 73
45 8 1.0 × 10–11 1.0 × 10–6 5.3 × 10–10 1.4 × 10–10 0.44 0.32 73
Table 4. Overview of the results for the antiandrogen control bicalutamide.
No. of  Replicates per Concentrations together Lowest  Highest IC50
Laboratory assays assay with 0.1 nM DHTa concentration (M) concentration (M) mean (M) SD (M) CV (%)
14 2 5 1.0 × 10–10 1.0 × 10–6 1.3 × 10–7 1.6 × 10–8 12
23 4 5 1.0 × 10–9 1.0 × 10–5 1.7 × 10–7 2.7 × 10–8 16
33 41 0 1.0 × 10–10 5.0 × 10–6 2.4 × 10–7 1.0 × 10–7 42
45 4 8 1.0 × 10–10 1.0 × 10–6 3.8 × 10–7 3.2 × 10–7 85
aLaboratory 2 used 0.1 nM R1881.
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Figure 3. Partial androgenic effects of antiandrogens in reporter gene assays. (A) Bicalutamide (mean ± SD
of three to ﬁve independent experiments); the effects of 0.1 nM DHT (or R1881) are also shown for compar-
ison. (B) Vinclozolin (assay 2 and assay 3; mean ± SD of three and four independent experiments, respec-
tively). Figure 2B and 2C show the maximal effect of the androgen control. an androgen-like decrease of cell count for
bicalutamide.
Figure 4 illustrates the concentration–
response curves for all four assays of bicalu-
tamide and the antiandrogenic chemicals vin-
clozolin and TCPM. Each laboratory derived
the IC50 values from the coincubation of cells
with 0.1 nM DHT (or R1881) and different
concentrations of antiandrogen, leading to a
subsequent increasing inhibition of the andro-
genic effect of DHT (or R1881). A concentra-
tion of 1 × 10–6M bicalutamide did not lead
to complete inhibition of the androgenic effect
in any of the assays. For calculation of IC50
values, the laboratories extrapolated the con-
centration–response curves to maximal effect.
Laboratories 2 and 3 disregarded the values
measured for coincubation of androgen with
1 × 10–5 M bicalutamide and > 3.0 × 10–6M
vinclozolin, respectively, for IC50 calculation
because of the slight androgenic activity of
these compounds at higher concentrations. All
four laboratories calculated comparable IC50
values, and the difference between the highest
and the lowest value was a factor of 3.
Table 5 and Figure 4 summarize and
illustrate the results on the activity of vinclo-
zolin and TCPM. With the exception of
assay 4, neither compound inhibited the
androgenic effect of 0.1 nM DHT (or
R1881) completely. Therefore, for calculation
of IC50 values, all laboratories extrapolated the
concentration–response curves to maximal
effect as for bicalutamide.
Table 2 shows the percentage of maximal
effect induced by 0.1 nM of the androgen
control. Because the response to anti-
androgens depends on the magnitude of this
response (the stronger the effect of the andro-
gen control, the greater competition of the
antiandrogen required), the different experi-
mental conditions used in the assays may
explain some of the observed differences in
IC50 values of the antiandrogens. Thus, labo-
ratories 1–4 tested the antiandrogens at 69,
53, 85, and 35% induction of maximum
androgen response, respectively, resulting in
the most favorable experimental conditions in
terms of sensitivity for detecting antiandrogens
for assay 4 and the least favorable conditions
for assay 3. 
In assays 2 and 3, vinclozolin showed slight
and moderate androgenic activity at the high-
est concentrations, respectively (Figure 3B).
These results agree with results obtained by
Wong et al. (1995), who found agonistic
activity of the vinclozolin metabolite M2 at
10 µM, and by Nellemann et al. (2003), who
observed agonistic activity of vinclozolin itself
at concentrations ≥ 3µ M. TCPM showed
cytotoxic effects ≥ 10 µM in test systems 1, 2,
and 3 (Figure 4).
For both chemicals, IC50 values as well as
calculated RAAP values remained similar
among all assays, although the percentage of the
maximal effect induced by 0.1 nM DHT (or
R1881) differed (Table 2). The highest and
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Figure 4. Concentration–response curves of the antiandrogen control bicalutamide, vinclozolin
(compound 1), and TCPM (compound 4) for all four assays. (A) Assay 1: antiandrogens plus 0.1 nM DHT.
(B) Assay 2: antiandrogens plus 0.1 nM R1881. (C) Assay 3: antiandrogens plus 0.1 nM DHT. (D) Assay 4:
antiandrogens plus 0.1 nM DHT. Values represent mean ± SD of at least three independent experiments.
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Table 5. Overview of the results for antiandrogenic compounds vinclozolin (compound 1) and TCPM (compound 4).
Compound, No. of  Concentrations Lowest  Highest IC50
laboratory assays tested concentration (M) concentration (M) mean (M) SD (M) RAAP mean SD CV (%)
Vinclozolin 
14 5 1.0 × 10–9 1.0 × 10–5 2.1 × 10–7 1.3 × 10–7 1.0 0.31 31
23 8 1.0 × 10–9 1.0 × 10–5 4.7 × 10–7 1.3 × 10–7 0.37 0.07 18
34 1 2 2.5 × 10–8 5.0 × 10–5 3.7 × 10–7 1.2 × 10–7 1.6 0.5 32
45 8 1.0 × 10–10 1.0 × 10–5 1.1 × 10–7 3.2 × 10–8 3.7 3.1 83
TCPM
13 5 1.0 × 10–9 1.0 × 10–5 5.7 × 10–7 1.4 × 10–7 0.22 0.04 16
23 7 1.0 × 10–9 1.0 × 10–5 8.0 × 10–7 1.8 × 10–7 0.22 0.04 20
34 1 2 2.5 × 10–8 5.0 × 10–5 3.1 × 10–6 1.4 × 10–6 0.086 0.03 36
45 8 1.0 × 10–9 1.0 × 10–5 1.1 × 10–6 7.6 × 10–8 0.37 0.33 90the lowest IC50 differed by a factor of 3 for
vinclozolin and a factor of 10 for TCPM.
Vinclozolin and bicalutamide had similar anti-
androgenic potencies, whereas TCPM had
about one fifth the potency of these com-
pounds. Two proliferation assays using
AR-positive human mammary carcinoma cell
lines have demonstrated the antiandrogenic
effect of TCPM (Körner et al. 1997, unpub-
lished data). The fact that all four assays unam-
biguously confirmed the antiandrogenic
properties of TCPM implicates environmental
relevance, because this compound is a ubiqui-
tous and highly bioaccumulating chemical and
we know little about its sources and toxicologic
properties (DeBoer 1997). 
The test systems are applicable to other
environmental antiandrogens such as
p,p´-DDE. In assay 4, DDE reduced DHT-
induced luciferase activity with an IC50 value
of 2.8 ± 0.8 × 10–6 M (n = 5), whereas cyto-
toxicity was observed at 1 × 10–4 M. In assay 3,
p,p´-DDE had an IC50 of 1.1 × 10–6 M
(Vinggaard et al., unpublished data).
When testing for agonists and antagonists
of AR, it is important to consider any cyto-
toxicity of test compounds to avoid classiﬁca-
tion of false positives. In assay 1 cytotoxicity
is assessed by inspecting the appearance of the
cells using an inverted microscope before the
cells are fixed. Cytotoxicity is recognized by
the presence of floating (dead) cells and the
presence of cytoplasmic vacuoles in those still
attached to the substrate. In this assay, ago-
nists inhibit cell proliferation and antagonists
overcome this inhibition; hence, evaluation of
cytotoxicity can also be made by testing
whether the inhibitory response observed in
the presence of a putative agonist is totally
reversed by excess antiandrogen. If the antag-
onist does not reverse the low cell yield, the
effect is considered cytotoxic. In the other
three assays, agonists increase and antagonists
decrease the expression of the reporter gene.
In the experimental conditions of this study,
in which antiandrogens were tested for both
agonistic and antagonistic effects, any cyto-
toxicity in the reporter gene assays was indi-
rectly revealed in the agonism test by an
inhibition of the transcriptional/translational
process (i.e., a decreased luciferase activity).
When only antagonism is tested, a very spe-
ciﬁc cytotoxicity test has been developed for
assays based on transient transfections. This
method involves transfection of cells with a
constitutive active AR expression vector that
lacks the ligand-binding domain of the
receptor (Kelce et al. 1995; Vinggaard et al.
2002). Cytotoxicity is measured directly at
the transcriptional/translational level with
this method. 
All assays showed comparable repeatability
for agonistic and antagonistic androgenic activ-
ity. The CVs of the IC50 values of bicalutamide
ranged from 12 to 85% (Table 4), and those
of the RAAP values ranged from 16 to 90%
(Table 5). Comparing CVs between the four
test systems, one should take into account that
the different number of independent experi-
ments (three to ﬁve) performed with the assays
inﬂuence the CV values. 
The various statistical programs and types
of regression used for calculation of EC50 and
IC50 values had little contribution to the dif-
ferences of the quantitative results between
the four assays. 
Conclusions
We compared four different cellular in vitro
assays for the detection of AR-mediated ago-
nistic and antagonistic effects of chemicals in
an interlaboratory study. All four test systems
produced comparable quantitative results for
two androgens and two antiandrogens. The
EC50 values calculated for the androgens and
the resulting androgenic potencies relative to
the positive control differed by less than a fac-
tor of 10 between the assays, with one excep-
tion. We saw this exception in assay 3, which
also shows a general greater sensitivity toward
detection of androgens. For the antiandrogenic
chemicals, differences of IC50 values and calcu-
lated relative antiandrogenic potencies between
the assays remained well within one order of
magnitude.
The CVs we obtained for the different
EC50 and IC50 values stayed generally within
the same range, and we found no obvious dif-
ferences in performance between assays.
Discrepancies among IC50 values may stem
from the fact that all laboratories tested the
antiandrogens with a fixed concentration of
0.1 nM androgen, giving rise to diverging
percentages of maximum induction. Different
metabolic capacities of each cell line for each
compound may also play a role. Differences
in RAP may reﬂect differences in metabolism
of the test compound, DHT, or both. This
could explain why 4-androsten-3,17-dione
showed considerably greater differences than
the other three test compounds and the posi-
tive controls. 
In summary, all four cellular in vitro
assays proved sensitive screening tools to
detect and quantify AR-mediated androgenic
and antiandrogenic effects of these chemicals
with reasonable accuracy. We did not design
this experiment to test which assay was best
for screening purposes, because a number of
other factors must be taken into account. All
laboratories have reported speciﬁcities of the
assays in the original publications, which
should be considered when deciding which
assay to use for screening purposes. In choos-
ing a test system to use, the equipment of the
laboratory, specific background and experi-
ence of the staff, and cost-effectiveness must
also be evaluated. 
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